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1. ABBREVIATIONS 
 
AP-1   activator protein-1 
BNP   B-type natriuretic peptide 
BW   body weight 
CK   creatine kinase 
CrP   creatine phosphate 
ERK1/2  extracellular signal-regulated kinase  
GSK-3 β  glycogen synthase kinase-3β 
HE   haematoxylin and eosin 
HQ   4-hydroxyquinazoline 
IR   ischemia-reperfusion 
ISO   isoproterenol hydrochloride 
JNK   c-jun N-terminal kinase 
LDH   lactate dehydrogenase 
MAPK  mitogen activated protein kinase 
MQ   2-merkapto-4(3H)-quinazolinone 
MTT   3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
NAD+   nicotinamide adenine dinucleotide 
NF-κB   nuclear factor-κB 
NIH   National Institutes of Health 
NMR   nuclear magnetic resonance 
PARP   poly(ADP-ribose) polymerase 
PDC-1α  pyruvate dehydrogenase complex-1α  
Pi   inorganic phosphate 
PI3K   phosphatidylinositol-3-kinase 
PKC   protein kinase C 
ROS   reactive oxygen species 
SEM   standard error of mean 
TBARS  thiobarbituric acid reactive substances 
TBS   TRIS-buffered saline 
TEF-1   transcriptional enhancer factor-1 
TL   length of right tibia 
TTC   triphenyltetrazolium-chloride 
WV   weight of ventricles 
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2. BACKGROUND 
 
2.1 MECHANISM OF CARDIOPROTECTION AFFORDED BY POLY(ADP-RIBOSE) POLYMERASE 
(PARP) ENZYME INHIBITION 
 Enhanced activation of poly(ADP-ribose) polymerase (PARP) enzyme is a major 
contributor to oxidative stress-induced cell dysfunction and tissue injury.1,2 Reactive oxygen 
species (ROS) and peroxynitrite formation expedites the ischemia-reperfusion-induced 
cardiac injury, and causes lipid peroxidation, protein oxidation and single-strand DNA 
brakes.3-5 Single-strand DNA brakes can activate the nuclear PARP, which ADP-ribosylates 
different nuclear proteins on the expense of cleaving NAD+. If PARP activation exceeds a 
certain limit, it can lead to cellular NAD+ and ATP depletion, ultimately resulting in cell 
death.1-4 We and other investigators have already shown that PARP inhibitors can efficiently 
reduce oxidative myocardial damage during ischemia-reperfusion both in isolated heart 
perfusion and in in vivo myocardial infarction models, furthermore PARP inhibition provided 
significant protection against postinfarction heart failure.3,6-9  
 Recent studies have however challenged the original conception that protection by 
PARP inhibitors exclusively rely on the preservation of NAD+ and ATP stores. In vitro data 
in Langendorff perfused heart model system indicated for the first time that PARP inhibitors 
decreased the ischemia-reperfusion-induced increase of mitochondrial ROS production and so 
all consequent oxidative damages. According to one possible argument, PARP inhibition by 
moderating cytoplasmic NAD+ loss can help to retain mitochondrial NAD+, and may prevent 
the decrease of the mitochondrial NAD+-linked substrate oxidation and ROS formation. As 
the nuclear PARP enzyme can probably not play any role in isolated mitochondria, it was also 
assumed, that PARP inhibitors bound to mitochondrial proteins such as mono-ADP-ribose 
transferase or NAD+-glycohydrolase that play role in the oxidative damage of mitochondria.3  
 Several studies have also suggested that PARP inhibitors may modify the activation 
state of signaling routes and gene expression.2,10-12 Importantly, there are strong evidences 
that PARP enzyme alters the function of a variety of transcription factors, and interfere with 
the expression of several proinflammatory genes by direct protein-protein interaction or by 
poly(ADP-ribosyl)ation.2,10,11 On one hand, protein-protein interaction is recognized as a 
mechanism for PARP to function as a specific transcriptional coactivator of nuclear factor 
(NF)-κB.13 It was also proven that PARP modulates transcription by direct interaction with 
Yin-Yang (YY)-1, activator protein (AP)-2, Oct-1 and transcriptional enhancer factor (TEF)-
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1.10 On the other hand, Amstad et al. have demonstrated that poly(ADP-ribosyl)ation is also 
an important event for the elongation and activation of protooncogenes.14 Several 
transcription factors such as TEF-1, TATA-binding protein and recombinant p50 and p65 NF-
κB subunits can also be poly(ADP-ribosyl)ated by PARP in vitro.10 The dual regulatory role 
of PARP, i.e., dependent or independent of the poly(ADP-ribosyl)ative activity, was further 
supported by studies demonstrating that genetic deletion of PARP, but not pharmacological 
inhibition of its activity, was able to reduce NF-κB binding in glial cells. However, 
pharmacological inhibition of the catalytic activity of PARP was able to reduce gene 
expression of inducible nitric oxide synthase.10 
 Nevertheless, to date, limited information is available on how PARP inhibition 
influences the signaling pathways during myocardial ischemia-reperfusion, or how PARP 
inhibition might modulate intracellular signaling during the progression of postinfarction 
remodeling and heart failure. There are data indicating that during reperfusion absence of 
PARP leads to the reduction of myocardial apoptosis, which is associated with reduced NF-
κB activation and altered gene expression of apoptotic regulators.15 Zingarelli et al. 
demonstrated for the first time that PARP-1 was requisite for the complete activation of c-jun 
N-terminal kinase (JNK) during reperfusion injury in vivo, while ischemia-reperfusion-
induced elevated JNK activity was reduced in PARP-/- mice.10 It was also demonstrated that 
mice with genetic ablation of PARP-1 exhibited a significant cardioprotection, which was 
associated with downregulation of the proinflammatory pathway of AP-1, whereas the anti-
inflammatory pathway of heat-shock factor (HSF)-1 was enhanced with consequent 
modification of gene expression of several inflammatory mediators such as heat shock protein 
(HSP)-70.10 Genetic or pharmacological inhibition of PARP-1 also reduced the adhesion 
molecule expression of P-selectin and intercellular adhesion molecule (ICAM)-1 and neutrofil 
infiltration in in vivo myocardial reperfusion injury and reduced the plasma release of 
inflammatory cytokines.16,17 Furthermore the loss of the PARP gene was associated with a 
significant reduction of the AP-1-dependent matrix metalloproteinase enzyme, which well 
correlated with the architectural damage and maintenance of myocyte alignment of the 
reperfused heart. Finally it was also demonstrated in an ex vivo ischemia-reperfusion model 
that the ischemia-reperfusion-induced activation of the cardioprotective Akt pathway could be 
further enhanced by the pharmacological inhibition of PARP.12 
 
 6 
2.2 PROTEIN KINASE CASCADES AND OXIDATIVE STRESS 
 Hypoxia-reoxygenation as well as other oxidative insults influence tissue survival 
partially via differential regulation of protein kinase cascades and inflammatory reactions.18,19 
Phosphatidylinositol-3-kinase (PI3K)-Akt and mitogen-activated protein kinase (MAPK) 
(including extracellular signal-regulated kinase (ERK1/2), JNK and p38-MAPK) signaling 
networks have all been shown to alter their activation state in response to oxidant injury and 
therefore could potentially participate in cell fate decisions.20,21 Signaling through Akt and 
ERK appears to be prosurvival in nature associated with growth factor receptor stimulation.22 
On the other hand, JNK and p38-MAPK activation was linked to apoptosis, but depending on 
the context and duration of activation, they can exert opposite effects, as well.23,24  
 Cardiac remodeling, ultimately culminating in heart failure, is also associated with 
alterations in intracellular signaling including the inhibition of glycogen synthase kinase-3ß 
(GSK-3ß) via phosphorylation by Akt, protein kinase C (PKC), p70-S6 kinase, p90-RSK and 
protein kinase A.25 These pathways and the MAP kinases have all been demonstrated to alter 
their activation state in response to hypertrophic stimuli and therefore may be responsible for 
myocardial hypertrophy.26-28 
 As recent findings in a rodent septic shock model showed that PARP inhibition 
increased the phosphorylation and activation of Akt and attenuated the lipopolysaccharide-
induced phosphorylation of ERK1/2, p90RSK and p38 MAP kinases, it suggested, that PARP 
inhibitors could modulate these signaling pathways which are also responsible for the cell-fate 
decisions in myocardial ischemia-reperfusion or in the development of cardiac hypertrophy.11 
  
2.3 EXPERIMENTAL MODELS OF CARDIAC OXIDATIVE INJURY 
 To elucidate the role of protein kinase signaling in the mechanism of cardioprotection 
afforded by PARP inhibitors, we utilized three experimental models. First, we investigated 
the effect of PARP inhibition on the recovery of energy metabolism in vitro in Langendorff 
perfused hearts during ischemia-reperfusion cycle, then the PARP inhibitor agent was tested 
in vivo in isoproterenol-induced myocardial infarction model.19,29 Third the PARP inhibitor 
compound was administered in a rat model of chronic heart failure after isoproterenol-induced 
myocardial infarction. As known, subcutaneous administration of the beta-adrenoceptor 
agonist isoproterenol induces extensive amount of cardiomyocyte necrosis, ranging from 
patchy subendocardial necrosis to transmural infarction, while maintaining patent coronary 
vasculature.29,30 The exact mechanism of isoproterenol-induced myocardial damage has not 
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been clarified, but a mismatch of oxygen supply versus demand following coronary 
hypotension and myocardial hyperactivity may offer the best explanation.30,31 It has been also 
demonstrated that ISO administration produces free radicals via β-adrenoceptor mechanism 
that affects the cell metabolism to such a degree that cytotoxic free radicals are formed 
producing myocardial necrosis.30 This effect results in both acute and chronic a deterioration 
of hemodynamic variables.29,31,32 The significant cell loss after the experimentally induced 
myocardial infarction is the initial insult that triggers the development of heart failure. The 
alteration in work load leads to consequent myocardial hypertrophy and finally ventricular 
enlargement and dilatation. Furthermore administration of high dosages of catecholamines is 
also followed by myocardial fibrosis, alterations in the collagen fibers or changes in the 
neurohormonal system. Finally injection of isoproterenol induces a syndrome in the rat that 
displays numerous typical characteristics of heart failure.30 
 
 In this study PARP inhibition was achieved by a novel compound, L-2286, which was 
derived from 2-mercapto-4(3H)-quinazolinone by alkylation with 1-(2-chloroethyl)piperidine 
(Fig 1.). L-2286 was chosen, because in in vitro PARP assay it exhibited significantly better 
PARP inhibitory activity than basic quinazolines such as 4-hydroxyquinazoline or 2-
merkapto-4(3H)-quinazolinone.33 
 
Figure 1. Chemical structure of L-2286 (2-[(2-Piperidin-1-yletil)thio]quinazolin-4(3H)-one). 
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3. AIMS OF THE STUDY 
 
The aim of this work was to provide evidence for a new molecular mechanism of the 
cardioprotective effect of PARP inhibition.  
1. To assess cardioprotection afforded by PARP inhibition  
a) We tested whether the novel quinazolinone derivate PARP inhibitor, L-2286 
facilitated the recovery of myocardial energy metabolism and prevented the 
oxidative injury during ischemia-reperfusion in a Langendorff-heart perfusion 
system. 
b) We tested whether L-2286 prevented oxidative myocardial damage during 
isoproterenol-induced myocardial infarction by determining serum necroenzyme 
levels and infarct size. 
c) We tested whether PARP inhibition protected against postinfarction heart failure 
and ventricular remodeling by analyzing histological changes and metabolic 
alterations.  
 
2. To provide evidence for a new additional cardioprotective mechanism, it was 
assessed, how PARP inhibition influenced the activation state of the intracellular 
signaling pathways responsible for myocyte cell survival or hypertrophic response. 
Therefore the phosphorylation states of the 
a) PI3-kinase/Akt pathway,  
b) protein kinase C 
c) and mitogen activated protein kinase cascades were examined by Western blotting.  
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4. MATERIALS AND METHODS 
 
4.1 HEART PERFUSION 
Adult male CFY-strain Sprague-Dawley rats weighing 300-380 g were used for the 
Langendorff heart perfusion experiments and the myocardial infarction model. The animals 
were housed in solid-bottomed polypropylene cages and received commercial rat diet and 
water ad libitum. The investigation conformed to the Guide for the Care and Use of 
Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 
85-23, revised 1996), and was approved by the Animal Research Review Committee of the 
University of Pecs Medical School. Rats were anesthetized with 200 mg/kg ketamine 
intraperitoneally and heparinized with sodium heparin (100 IU/rat i.p.). Hearts were perfused 
via the aorta according to the Langendorff method at a constant pressure of 70 mmHg, at 37oC 
as described previously.3 The perfusion medium was a modified phosphate-free Krebs-
Henseleit buffer consisting of 118 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 25 mM NaHCO3, 
11 mM glucose and 0.6 mM octanoic acid and, in the treated group, L-2286 in 10 and 20 µM 
concentrations. The perfusate was adjusted to pH 7.40 and bubbled with 95% O2 and 5% CO2 
through a glass oxygenator. After a washout, non-recirculating period of 10 min, hearts were 
either perfused under normoxic conditions for 10 min, or were subjected to a 30-min global 
ischemia by closing the aortic influx and reperfused for 15 min. The experimental compound 
was administered into the perfusion medium at the beginning of normoxic perfusion. During 
ischemia hearts were submerged into perfusion buffer at 37oC. Hearts were freeze-clamped at 
the end of each perfusion. 
 
4.2 NMR SPECTROSCOPY 
NMR spectra were recorded with a Varian UNITYINOVA 400 WB instrument. 31P 
measurements (161.90 MHz) of perfused hearts were run at 37oC in a Z•SPEC in a 20-mm 
broadband probe (Nalorac Co., Martinez, CA, USA), applying GARP-1 proton decoupling 
(γB2=1.2 kHz) during acquisition. Field homogenity was adjusted by following the 1H signal 
(w1/2=10-15 Hz). Spectra were collected with a time resolution of 3 min by accumulating 
120 transients in each free induction decay (FID). 45o flip angle pulses were employed after a 
1.25 s recycle delay and transients were acquired over a 10 kHz spectral within 0.25 s, and the 
acquired data points (5000) were zero filled to 16 K. Under the above circumstances the 
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relative concentrations of the species can be taken proportional to the peak areas, because 
interpulse delays exceeded 4-5xT1 values of the metabolites to be analyzed in 31P 
experiments. 
 
4.3 LIPID PEROXIDATION AND PROTEIN CARBONYL CONTENT 
Lipid peroxidation was estimated from the formation of thiobarbituric acid reactive substances 
(TBARS). TBARS were determined using a modification of a described method.34 Cardiac 
tissue was homogenized in 6.5% trichloroacetic acid (TCA) and a reagent containing 15% TCA, 
0.375% thiobarbituric acid (TBA) and 0.25% HCl was added, mixed thoroughly, heated for 15 
min in a boiling water bath, cooled, centrifuged and the absorbance of the supernatant was 
measured at 535 nm against a blank that contained all the reagents except the tissue homogenate. 
Using malondialdehyde standard, TBARS were calculated as nmol/g wet tissue. 
To measure protein carbonyl content, 50 mg of frozen heart tissue were homogenized with 1 ml 
4% perchloric acid and the protein content was collected by centrifugation. The protein carbonyl 
content was determined by means of the 2,4-dinitrophenylhydrazine-method.35 
 
4.4 MYOCARDIAL INFARCTION MODEL 
Myocardial infarct was induced by subcutaneous injection of 80 mg/kg isoproterenol 
hydrochloride (ISO) (Sigma-Aldrich Co, Budapest, Hungary), while physiological saline (1 
ml/kg) was given to control rats intraperitoneally. ISO solutions were prepared with sterile 
distilled water immediately before injection. ISO-treated animals were divided into two 
groups: while the ISO group received repeated injections of saline, the ISO+L-2286 group 
received L-2286 10 min before (10 mg/kg) and every hour for 5 hours (3 mg/kg) after ISO 
administration. Electrocardiogram was made before and hourly (for 5 hours) after ISO 
administration (Schiller AG electrocardiograph, Switzerland). 
 
4.5 INFARCT SIZE MEASUREMENT 
24 h after the ISO administration, animals were sacrificed, hearts were removed and kept 
overnight at -20oC. Frozen ventricles were sliced into 2-3 mm thick sections and then 
incubated in 1% triphenyltetrazolium-chloride (TTC) at 37oC in 0.2 M Tris buffer (pH 7.4) 
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for 30 min. While the normal myocardium was stained brick red, the infarcted areas remained 
unstained. Size of the infarcted area was estimated by the volume and weight method.36 
 
4.6 SERUM NECROENZYME DETERMINATION 
Serum lactate dehydrogenase (LDH) and creatine kinase (CK) levels were determined from 
blood samples collected 24 h after ISO administration. Myocardial enzyme activities were 
measured by standard methods as described earlier.37,38 
 
4.7 CHRONIC HEART FAILURE MODEL 
350-380 g male CFY rats received two subcutaneous injections (separated by a 24-hour 
interval) of 80 mg/kg isoproterenol.31 Twenty-four hours after the second injection the 
surviving animals were randomly assigned to receive either 5 mg/kg L-2286, or water daily. 
The PARP inhibitor treatment was delayed 24 h to avoid the decrease of infarct size by the 
PARP inhibition.9 L-2286 was given for 8 weeks. At the end of 8 weeks body weights were 
measured and standard ECG was recorded to determine the R wave amplitude and J point 
depression (lead II). Animals were subsequently sacrificed, their hearts were removed, the 
atria and great vessels were trimmed from the ventricles and the weight of the ventricles was 
measured. It was then normalized to the body weight and the length of right tibia. Hearts were 
then freeze-clamped or fixed in 10% formalin. 
 
4.8 DETERMINATION OF PLASMA B-TYPE NATRIURETIC PEPTIDE 
Blood samples were collected into the Lavender Vacutaner tubes containing EDTA and 
aprotinin (0.6 TIU/ml of blood), centrifuged at 1600 g for 15 minutes at 4oC. Plasma were 
collected and kept at –70oC. Plasma B-type natriuretic peptide-45 (BNP-45) levels were 
determined by enzyme immunoassay method (BNP-45, Rat EIA Kit, Phoenix 
Pharmaceuticals Inc., CA, USA). 
 
4.9 MEASUREMENT OF MITOCHONDRIAL ENZYME ACTIVITY 
NADH:cytochrome-c oxidoreductase was measured as described previously.3 Enzyme 
activity was determined by measuring the rate of cytochrome c reduction at 550 nm in a 
medium containing 50 mM sodium-phosphate, 1 mM sodium-azide, 1.5 mM NADH and 50-
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75 µg mitochondrial protein/ml, pH 7.5. The reaction was started by addition of 40 µl 
cytochrome c. 
 
4.10 HISTOLOGY 
Ventricles fixed in formalin were sliced, and embedded in paraffin. 5 µm thick sections were 
cut serially from base to apex. 10 to 12 slices at 1-mm intervals were stained with 
haematoxylin and eosin (HE). The sections were mounted on slides and projected at a 
magnification of 40x and photomicrographs were taken. Mean myocyte diameters on HE 
stained sections were calculated by measuring 100 cells per specimen in the region of the cell 
nucleus using the two-point distance function of the TelPath analyzer system (bollman.com, 
2000). Type III collagen was stained as a marker of interstitial fibrosis on frozen sections, 5 
µm thick by the Vector M.O.MTM Kit (Vector Laboratories Inc., Burlingame, CA, USA) 
staining procedure. After fixing and dehydrating, sections were washed in TRIS-buffered 
saline (TBS) containing 0.5% Tween 20, pH 7.6. To block the endogenous peroxidase 
activity, sections were incubated in 3% H2O2 then washed in TBS. After 1 h incubation with 
M.O.M.TM mouse IgG blocking reagent (containing 20% normal rat serum) sections were 
washed in TBS, and incubated in the working solution of M.O.M.TM diluent for 5 min. Primary 
mouse antisera against type III collagen (1:1000, Monoclonal Anti-Collagen, Type III, Sigma-
Aldrich Co, Budapest, Hungary) diluted in M.O.M.TM diluent reacted at room temperature for 
30 min, followed by two 2-minute rinses in TBS. Biotinylated Anti-Mouse IgG Reagent was 
the applied for 10 min and sections were washed twice for 2 min in TBS. VECTASTATIN 
ABC Reagent was applied for 5 min that was followed by two 2-minute rinses in TBS. 
Sections were then stained with Vector NovaRED Substrate (Vector Laboratories Inc., 
Burlingame, CA, USA) for five min, washed in distilled water, dehydrated, mounted on slides 
and projected at a magnification of 10x. The sections were quantified with the NIH ImageJ 
analyzer system. All histologic and immunohistological samples were examined by an 
investigator in a blinded fashion. 
 
4.11 WESTERN BLOT ANALYSIS 
Fifty milligrams of heart samples were homogenized in ice-cold Tris buffer (50 mM, pH=8.0) 
and harvested in 2x concentrated SDS-polyacrilamide gel electrophoretic sample buffer. 
Proteins were separated on 12% SDS-polyacrilamide gel and transferred to nitrocellulose 
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membranes. After blocking (2 h with 3% nonfat milk in Tris-buffered saline), membranes 
were probed overnight at 4oC with antibodies recognizing the following antigenes: phospho-
specific Akt-1/protein kinase B-α Ser473 (1:1000), nonphosphorylated Akt/PKB (1:1000), 
phospho-specific glycogen synthase kinase (GSK)-3β Ser9 (1:1000), phospho-specific 
extracellular signal-regulated kinase (ERK1/2) Thr183-Tyr185 (1:1000), phospho-specific p38 
mitogen-activated protein kinase (p38-MAPK) Thr180-Gly-Tyr182 (1:1000), phospho-specific 
c-Jun N-terminal kinase (JNK) (1:1000), phospho-specific protein kinase C (PKC) (pan) ßII 
Ser660 (1:1000), phospho-specific protein kinase C α/ßII (PKCα/ßII) Thr638/641 (1:1000), 
phospho-specific protein kinase C δ Thr505 (1:1000), phospho-specific protein kinase C δ 
Ser643 (1:1000; Cell Signaling Technology, Beverly, MA, USA), nonphosphorylated PKC 
(1:1000), N-terminal domain of actin (1:10000; Sigma-Aldrich Co, Budapest, Hungary). 
Membranes were washed six times for 5 min in Tris-buffered saline (pH 7.5) containing 0.2% 
Tween (TBST) before addition of goat anti-rabbit horseradish peroxidase-conjugated 
secondary antibody (1:3000 dilution; Bio-Rad, Budapest, Hungary). Membranes were washed 
six times for 5 min in TBST and the antibody-antigen complexes were visualized by means of 
enhanced chemiluminescence. The results of Western blots were quantified by NIH ImageJ 
program. 
 
4.12 STATISTICAL ANALYSIS 
Statistical analysis was performed by analysis of variance and all of the data were expressed 
as the mean ± SEM. Significant differences were evaluated by use of unpaired Student's t-test 
and p values below 0.05 were considered to be significant. 
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5. RESULTS 
 
5.1 L-2286 PROMOTED THE POSTISCHEMIC RECOVERY OF MYOCARDIAL ENERGY STORES 
Energy metabolism of Langendorff perfused hearts was monitored in the magnet of a 31P 
NMR spectroscope enabling the detection of changes in high-energy phosphate intermediates. 
Ischemia induced a rapid decrease in ATP and creatine phosphate levels and a fast evolution 
of inorganic phosphate (Fig. 2A-C). In our experimental setting, high-energy phosphate 
intermediates recovered only partially in untreated hearts during the 15-min reperfusion 
phase. On the other hand, L-2286 facilitated the recovery of creatine phosphate and ATP in  
 
Figure 2. L-2286 attenuates ischemia-reperfusion-induced injury of isolated hearts. Time-course of creatine 
phosphate (A), ATP (B) and inorganic phosphate levels (C) as measured by 31P NMR spectroscopy. Values are 
given as the mean±SEM for five experiments. IR: ischemia-reperfusion. *Significant difference from control 
untreated sample (p<0.01). 
 
5.2 L-2286 ATTENUATED THE ISCHEMIA-REPERFUSION-INDUCED LIPID PEROXIDATION AND 
PROTEIN OXIDATION 
In this study, ischemia-reperfusion increased the amount of TBARS compared to the 
normoxic hearts (from 24.4 ± 1.1 to 43.2 ± 1.25 nmol/g wet tissue, p<0.001). However, 10 
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both 10 and 20 µM concentrations (Fig. 
2A-B). Consistent with the high-energy 
phosphate data, L-2286 also promoted 
the faster and more complete reutilization 
of inorganic phosphate during 
reperfusion (Fig. 2C). 
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µM L-2286 administration significantly reduced the formation of TBARS (to 30.2 ± 1.7 
nmol/g wet tissue, p<0.01) compared to untreated hearts, indicating that L-2286 prevented the 
ischemia-reperfusion-related lipid peroxidation. On the other hand, ischemia-reperfusion 
markedly elevated the level of protein oxidation (from 1.2 ± 0.05 to 2.2 ± 0.1 µmol/g wet 
tissue, p<0.001); however, L-2286 significantly attenuated (p<0.01) the increase in the 
quantity of protein-bound aldehyde groups (to 1.5 ± 0.08 µmol/g wet tissue). 
 
5.3 ENHANCED AKT AND MAP KINASE ACTIVATION UPON L-2286 TREATMENT DURING 
ISCHEMIA-REPERFUSION 
The moderate phosphorylation of Akt under normoxic conditions in our study increased after 
ischemia-reperfusion; nevertheless, L-2286 treatment further enhanced the activation of Akt 
(Fig. 3A). GSK-3β was not phosphorylated during normoxia, but became moderately 
phosphorylated after ischemia-reperfusion and strongly phosphorylated upon L-2286 
treatment. As GSK-3β is phosphorylated by Akt leading to its inactivation, the marked 
phosphorylation of GSK-3β in treated hearts is in accordance with enhanced Akt activation in 
the same tissue samples (Fig. 3A). Interestingly, L-2286 also brought about Akt as well as 
GSK-3β phosphorylation during the 10-min normoxic perfusion, which is in clear contrast 
with the untreated normoxic condition where moderate or no phosphorylation was observed. 
Additionally, L-2286 promoted the phosphorylation of ERK, p38-MAPK as well as JNK both 
in normoxic and ischemic-reperfused hearts (Fig. 3B). Ischemia-reperfusion by itself only 
slightly increased the phosphorylation of ERK, p38-MAPK and JNK. 
 
5.4 L-2286 INHIBITED THE ISOPROTERENOL-INDUCED MYOCARDIAL CELL LOSS 
ISO administration results in compromised cell membrane integrity and causes necroenzyme 
release from cardiomyocytes. In comparison with the control group, ISO administration 
significantly increased CK and LDH release from the injured cardiomyocytes (p<0.01). By 
contrast, L-2286 treatment significantly reduced CK and LDH levels in the serum (p<0.05) 
(Fig. 4A-B). ECG monitoring of the heart rate revealed that L-2286 did not interfere with the 
tachycardia elicited by ISO administration (data not shown). 
As the TTC staining in five consecutive samples demonstrated, ISO administration caused a 
large, 21.1 ± 2 % infarct of the ventricles. In the meantime, L-2286 treatment significantly 
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reduced the infarct size to 8.9 ± 1 % (p<0.05). TTC staining of control hearts rendered no 
appreciable infracted area. 
A. 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. L-2286 promotes Akt, ERK, p38-MAPK and JNK phosphorylation in ischemic-reperfused 
hearts. Western blot analysis of Akt-1 and GSK-3β phosphorylation (A) as well as ERK, p38-MAPK and JNK 
phosphorylation (B). Actin is shown as loading control. N: normoxic perfusion; IR: ischemia-reperfusion. 
Representative immunoblots from five experiments and densitometric evaluation are demonstrated. *Significant 
difference from normoxic sample (p<0.01). †Significant difference from IR sample (p<0.01). 
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Figure 4. L-2286 inhibits the isoproterenol-induced in vivo myocardial injury. Serum levels of lactate 
dehydrogenase (A) and creatine kinase (B) were measured in the serum 24 hours after ISO administration. 
Values are given as the mean±SEM for at least five experiments. *Significant difference from control untreated 
sample (p<0.01). 
 
5.5 L-2286 ENHANCED AKT-1, ERK AND P38-MAPK, WHILE REDUCED JNK 
PHOSPHORYLATION IN ISOPROTERENOL-INDUCED MYOCARDIAL INJURY 
 
While ISO administration rapidly 
increased Akt phosphorylation, co-
treatment with L-2286 could further 
enhance the activation of the Akt protein 
(Fig. 5A). Subsequent elevation in GSK-3β 
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triggered a more pronounced 
phosphorylation than ISO by itself (Fig. 
5A). 
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Figure 5. L-2286 increases Akt-1, ERK, and p38-MAPK, while suppresses JNK phosphorylation in 
isoproterenol-induced myocardial injury. Western blot analysis of Akt-1 and GSK-3β phosphorylation (A) as 
well as ERK, p38-MAPK and JNK phosphorylation (B) 0, 0.5, 2, 4 and 24 hours after ISO administration. Actin 
is shown as loading control. Representative immunoblots from five experiments and densitometric evaluation are 
demonstrated. *Significant difference from control untreated sample (p<0.01). †Significant difference from L-
2286-treated samples (p<0.01). 
While ISO administration led to 
higher ERK phosphorylation 
only after 24 hours, L-2286 co-
treatment accelerated this 
process immediately after ISO 
injection (Fig. 5B). Similarly, 
the initial p38-MAPK 
phosphorylation level rather 
diminished following ISO 
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after 24 hours (Fig. 5B). By 
contrast, the ISO-induced 
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higher phosphorylation levels than the ISO 
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baseline at 24 hours (Fig. 5B). In contrast to our ischemia-reperfusion data, L-2286 reduced 
the ISO-induced JNK phosphorylation throughout the entire experiment (Fig. 5B). 
 
5.6 PARP INHIBITION IMPROVES GRAVIMETRIC PARAMETERS IN ISO-INDUCED CHRONIC 
HEART FAILURE 
After myocardial infarction the initial loss of myocardium can initiate progressive ventricular 
hypertrophy. The surviving myocytes undergo hypertrophy showing increases in both cell 
length and diameter. In this study gravimetry performed 8 weeks after ISO-induced 
myocardial infarction showed significantly elevated ventricular weight (p<0.05) as well as 
ventricular weight normalized to body weight (p<0.01) and to tibia length (p<0.001) (Table 
1). However, L-2286 treatment prevented the unfavourable changes in these parameters 
(Table 1). Additionally, L-2286 administration also attenuated the ISO-induced weight gain 
(Table 1). 
 
 
Table 1. PARP inhibition improves gravimetric parameters in ISO-induced chronic heart failure. 
Conditions for performing gravimetry are detailed in Methods. BW: Body weight, WV: Weight of ventricles, 
TL: Length of right tibia, WV/BW: Weight of ventricles/body weight ratio, WV/TL: Weight of ventricles/length 
of tibia, ISO: animals 8 weeks after ISO administration; ISO+L-2286: animals treated with L-2286, 8 weeks 
after ISO administration. All values are means±SEM, *p<0.05 (vs. Control group), **p<0.05 (vs. ISO group). 
 
5.7 L-2286 MODERATED THE ELECTROCARDIOGRAPHIC CHANGES ASSOCIATED WITH CHRONIC 
HEART FAILURE 
Decreased R wave amplitude (0.18 ± 0.02 vs. 0.59 ± 0.03 mV, p<0.01) as well as J point 
depression (-0.04 ± 0.04 vs. 0.12 ± 0.01) were observed on the electrocardiogram of the ISO 
group 8 weeks after myocardial infarction. These electrocardiographic changes were 
 Control ISO ISO+L-2286 
BW (g) 403 ± 53.7 431.3 ± 28.6* 397.2 ± 22.3** 
WV (g) 1.02 ± 0.078 1.132 ± 0.123* 0.977 ± 0.074** 
WV/BW (g/kg) 2.51 ± 0.14 2.62 ± 0.19* 2.53 ± 0.15** 
WV/TL (g/mm) 0.022 ± 0.001 0.025 ± 0.0025* 0.023 ± 0.0013** 
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significantly improved (0.4 ± 0.03 and 0.05 ± 0.02 mV, R wave amplitude and J point, 
respectively, p<0.05) by L-2286 treatment. 
 
5.8 L-2286 INHIBITED THE HEART FAILURE-INDUCED ELEVATION OF PLASMA BNP LEVEL 
Elevation of plasma BNP level is associated with the severity of heart failure, while low 
plasma BNP concentrations provide strong evidence against heart failure. Plasma BNP level 
in our study showed a significant increase in the ISO group 8 weeks after myocardial 
infarction (3.5 ± 0.22 ng/ml) in comparison with the control group (2.2 ± 0.18 ng/ml, p<0.01). 
On the other hand, L-2286 treatment significantly reduced the plasma BNP level (2.56 ± 0.16, 
p<0.05) suggesting that the PARP inhibition was able to decrease the severity of 
postinfarction heart failure. 
 
5.9 L-2286 PREVENTED THE OXIDATIVE DAMAGE OF RESPIRATORY COMPLEXES IN CHRONIC 
HEART FAILURE 
Ventricular remodeling is accompanied by altered mitochondrial energy metabolism. Under 
our experimental conditions, chronic heart failure induced a partial inactivation of respiratory 
complexes I-III assessed by the measurement of NADH:cytochrome c oxidoreductase activity 
(p<0.01) (Fig. 6A). As a contrast, L-2286 could partially protect (p<0.05) NADH:cytochrome 
c oxidoreductase activity in the failing heart mitochondria. Importantly, the expression of 
mitochondrial enzymes (including NADH dehydrogenase (complex I) 43, 53, 70 subunits and 
pyruvate dehydrogenase complex-1α) showed no changes in either the untreated or L-2286-
treated heart samples, therefore the reduced activity of mitochondrial enzymes can be 
completely attributed to posttranslational oxidative injury (Fig. 6B). 
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Figure 6. L-2286 prevented the oxidative damage of respiratory complexes in chronic heart failure. A. 
Activity of NADH:cytochrome c oxidoreductase in 
isolated mitochondria from failing rat hearts. 
Mitochondrial enzyme activities were measured as 
described in Methods. ISO: animals 8 weeks after ISO 
administration; ISO+L-2286: animals treated with L-
2286, 8 weeks after ISO administration. Data are 
expressed as the percent of control values 
(means±SEM), *p<0.05 (vs. ISO group), **p<0.01 (vs. 
Control group). B. Expression of mitochondrial 
enzymes (NADH dehydrogenase complex (complex I) 
- 43, 53, 70 subunit, pyruvate dehydrogenase complex-
1α) in heart failure rats. Conditions for Western blot 
analysis were detailed in Methods. Representative 
immunoblots from five experiments with similar results 
and densitometric evaluation are shown. PDC-1α: 
pyruvate dehydrogenase complex-1α; ISO: animals 8 
weeks after ISO administration; ISO+L-2286: animals 
treated with L-2286, 8 weeks after ISO administration. 
 
 
 
 
 
5.10 L-2286 ATTENUATED THE MYOCARDIAL HYPERTROPHY AND INTERSTITIAL COLLAGEN 
DEPOSITION 
Histological analysis revealed marked myocyte hypertrophy in failing rat hearts compared to 
the control group (p<0.001) (Fig. 7A-B). In addition, interstitial type III collagen deposition 
increased from 12.2 ± 1.2 % in control hearts to 18.4 ± 1.4 % in ISO-treated animals 
(p<0.001) (Fig. 8A-B). Nevertheless, L-2286 treatment significantly decreased the mean 
myocyte diameter (p<0.005) (Fig. 7C-D) and prevented the interstitial fibrosis (type III 
collagen deposition 15.4 ± 1.4 %) (p<0.01) (Fig. 8C-D). 
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Figure 7. L-2286 attenuated the ISO-induced myocardial hypertrophy. Sections obtained from hearts of 
control (A), ISO-treated (B), and ISO+L-2286-treated animals (C) were stained with hematoxylin and eosin and 
mean myocyte diameters were calculated (D). Conditions for measurement of mean myocyte diameter were 
detailed in Methods. ISO: animals 8 weeks after ISO administration; ISO+L-2286: animals treated with L-2286, 
8 weeks after ISO administration. Values are given as means±SEM, *p<0.005 (vs. ISO group), **p<0.001 (vs. 
Control group). 
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Figure 8. L-2286 reduced the ISO-induced interstitial collagen deposition. Sections obtained from hearts of 
control (A), ISO-treated (B), and ISO+L-2286-treated animals (C) were immunostained with an antibody against 
type III collagen; additionally, densitometric evaluation is shown (D). Conditions for immunohistology were 
detailed in Methods. ISO: animals 8 weeks after ISO administration; ISO+L-2286: animals treated with L-2286, 
8 weeks after ISO administration. Values are given as means±SEM, *p<0.001 (vs. Control group), **p<0.01 (vs. 
ISO group). 
 
5.11 L-2286 REDUCED GSK-3Β AND PKC PHOSPHORYLATION IN FAILING MYOCARDIUM 
GSK-3β was slightly phosphorylated in control animals, but became strongly phosphorylated 
8 weeks after myocardial infarction in the ISO group (Fig. 9A). However, this strong 
phosphorylation was diminished by L-2286 administration (Fig. 9A). The moderate Akt 
phosphorylation present in the control samples slightly increased in the ISO group, but the L-
2286 treatment did not influence the phosphorylation state of Akt (Fig. 9A). The level of 
GSK-3β phosphorylation was not in accordance with that of Akt, one of the upstream kinases 
of GSK-3β causing its inhibition, therefore the L-2286-induced decrease in GSK-3β 
phosphorylation was probably independent of Akt. 
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 The overall (pan) phosphorylation state of protein kinase C was moderate in control 
animals, but became strongly enhanced 8 weeks after myocardial infarction without any 
change in the expression of total PKC (Fig. 9B). As far as the PKC isoforms are concerned, 
PKC α/βII and PKC δ (Ser643) seemed to be responsible for the ISO treatment-associated 
increased pan PKC phosphorylation (Fig. 9B). Most importantly and in concert with the 
GSK-3β phosphorylation state, the enhanced phosphorylation of pan PKC, PKC α/βII and 
PKC δ (Ser643) seen in the postinfarcted samples was significantly attenuated by the PARP 
inhibitor treatment. Since GSK-3β can be phosphorylated by PKC leading to its inactivation, 
we propose that the PARP inhibition-caused reduced GSK-3β phosphorylation was probably 
mediated by the PKC pathway. The phosphorylation state of PKC δ (Thr505) however 
remained unchanged in response to any treatment. 
 
5.12 L-2286 HAD NO INFLUENCE ON THE PHOSPHORYLATION OF MAP KINASES 
Extracellular signal-regulated kinase (ERK) was moderately phosphorylated in control 
samples and remained so in ISO-treated as well as ISO+L-2286-treated hearts (Fig. 9C). In 
contrast, the moderate phosphorylation of both p38-MAPK and c-jun N-terminal kinase 
(JNK) seen in control hearts was elevated in heart failure animals (ISO group), but L-2286 
could not mitigate the phosphorylation of these kinases (Fig. 9C). 
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Figure 9. C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. L-2286 treatment inhibits hypertrophic stimuli-induced GSK-3ß phosphorylation via protein 
kinase C signaling in chronic heart failure. A. Western blot analysis of Akt and GSK-3β phosphorylation and 
densitometric evaluation are shown. B. Western blot analysis of pan PKC, PKC α/β, PKC δ (Thr505) and PKC δ 
(Ser643) phosphorylation and densitometric evaluation are shown. C. Western blot analysis of ERK, p38-MAPK 
and JNK phosphorylation and densitometric evaluation are shown. Actin is shown as loading control. ISO: 
animals 8 weeks after ISO administration; ISO+L-2286: animals treated with L-2286, 8 weeks after ISO 
administration. Representative immunoblots from five experiments with similar results are shown, *p<0.001 (vs. 
Control group), **p<0.001 (vs. ISO group). 
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6. DISCUSSION 
 
 This study gave first insight into a novel mechanism of cardioprotection by a novel 
PARP inhibitor L-2286 in isolated ischemic-reperfused hearts, in in vivo isoproterenol-
induced myocardial injury and in an experimental model of chronic heart failure. PARP 
inhibition was first shown to beneficially influence the activation of Akt signaling pathway 
and the MAPK cascade in two animal models of myocardial ischemia and reperfusion. 
Furthermore PARP inhibition beneficially influenced the progression of myocardial 
hypertrophy and remodeling following myocardial infarction eventually by activating the 
antihypertrophic glycogen synthase kinase-3ß via blocking protein kinase C signaling. 
6.1 CARDIOPROTECTION AFFORDED BY PARP INHIBITION IN MYOCARDIAL ISCHEMIA-
REPERFUSION 
 Massive PARP activation induced by oxidative stress after ischemia-reperfusion 
contributes to myocardial cell death and the subsequent inflammatory reactions.2 
Consequently, PARP inhibition was shown to exert protection against oxidative injury in cell 
cultures and ex vivo and in vivo animal models of regional or global cardiac, brain or renal 
ischemia-reperfusion.1-4 Therefore, pharmacological inhibition of PARP or PARP gene 
ablation improved the functional and metabolic recovery of postischemic myocardium and 
reduced infarct size in various models.6,7,10 
 Hereby L-2286 was demonstrated to promote the postischemic recovery of myocardial 
energy metabolism in Langendorff heart perfusion system. L-2286 helped to preserve the 
high-energy phosphate intermediates during reperfusion as shown by 31P NMR spectroscopic 
studies. Moreover, L-2286 facilitated the rapid and more complete consumption of inorganic 
phosphates during reperfusion. Reutilization of the latter bears crucial importance because 
excessive amounts of inorganic phosphates, calcium and reactive oxygen species are the most 
potent triggers of mitochondrial permeability transition, which compromises the integrity of 
the mitochondrial membranes ultimately leading to apoptosis.19 The improved metabolic 
recovery in the presence of L-2286 was accompanied by decreased myocardial oxidative 
damage, i.e. lipid peroxidation and protein oxidation. 
 In accordance with Langendorff studies, the isoproterenol-induced myocardial damage 
in vivo was also significantly attenuated by L-2286 treatment, as it was proved by reduced 
cardiac necroenzyme (CK and LDH) release and smaller infarct size in ISO+L-2286-treated 
compared to ISO-treated animals. Notably, isoproterenol, a β-adrenergic agonist causes 
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extensive cardiomyocyte necrosis, which may be induced by a mismatch of oxygen supply 
versus demand and additionally, by enhanced free radical formation.29-32  
 
6.2 CARDIOPROTECTION AFFORDED BY PARP INHIBITION IN CHRONIC HEART FAILURE  
 The experimental PARP inhibitor compound L-2286 was also tested in rats with 
failing heart following isoproterenol-induced myocardial infarction. As heart failure is one of 
the leading causes of morbidity and mortality worldwide, the effect of PARP inhibition on the 
progression of heart failure is worth to be elucidated.39 PARP inhibition already represents a 
potential clinical approach to fight against myocardial remodeling: as it has been previously 
reported, carvedilol, an antiadrenergic drug used, among others, to treat the hypertrophic and 
failing heart, exhibited antioxidant and PARP-inhibitory properties.5 
 So far PARP inhibition have been reported to moderate cardiac dysfunction and 
improve vascular relaxation in postinfarcted rats, however, the effects of PARP inhibition on 
the (sub)cellular and metabolic parameters in the failing heart are still elusive.9 We therefore 
examined how L-2286 interferes with the progression of postinfaction heart failure, including 
changes in cellular mass, interstitial matrix composition, metabolic parameters, gene 
expression and intracellular signaling. 
 Cardiac remodeling is characterized by inadequate myocyte hypertrophy and 
accumulation of extracellular matrix structural proteins (fibrillar collagen, type I and III 
collagen), which induce tissue stiffness and adversely affect myocardial viscoelasticity, 
ultimately leading to diastolic and systolic dysfunction.26,40,41 In addition, perivascular fibrosis 
and disorganized hypertrophy can exhaust the coronary blood flow reserve and the 
consequent hypoperfusion may provoke myocardial ischemia.26,31 In this study L-2286 
exerted a beneficial effect on the progression of postinfarction remodeling by attenuating 
myocardial hypertrophy and interstitial deposition of type III collagen in the failing hearts. 
 Cardiac hypertrophy and failure can also be characterized by severe dysfunction of 
mitochondrial energy and substrate metabolism involving impaired mitochondrial function, 
decline in high-energy phosphates, reduced oxygen consumption and decreased tissue content 
and activity of complex I through IV of the respiratory chain.42 Similar to literature data, the 
activity of complex I to III (NADH:cytochrome c oxidoreductase) has dropped in our heart 
failure model accompanied with unaltered expression of either complex I (43, 53, 70 subunit) 
or pyruvate dehydrogenase complex (1α subunit). Since the dysfunction of these enzymes is 
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mainly attributed to posttranslational inactivation by reactive oxygen species, this event was 
efficiently prevented by PARP inhibition. 
 In response to hypertrophic stimuli such as left ventricular wall stretch and volume 
overload, cardiac fetal-like gene program is initiated entailing, among others, the expression 
and secretion of natriuretic factors (BNP, ANP).26,40,43,44 The increased release of plasma B-
type natriuretic peptide from the ventricles, and elevated BNP concentration specifically 
signals impaired left ventricular function and chronic heart failure.25,45 In concert with this, 
plasma BNP level increased in the postinfarcted animals, which was moderated by L-2286 
treatment. 
6.3 EFFECT OF PARP INHIBITION ON CELLULAR SIGNALING IN MYOCARDIAL ISCHEMIA-
REPERFUSION 
 Reports from our and other laboratories have recently challenged the notion that the 
protection by PARP inhibition is solely attributable to the preservation of cellular NAD+ and 
ATP pools.2,3,10,11,12,15,46,47 These studies suggested that PARP blockade might also modulate a 
diverse array of signaling cascades and interfere with the expression of several genes in 
inflammatory processes and cardiac ischemia-reperfusion. In this respect, these findings 
raised the important prospect that the targeting of PARP might ameliorate the myocardial 
dysfunction by interrupting the adverse processes at the signal transduction level.  
 This study demonstrated for the first time that PARP inhibitors could promote Akt 
activation during cardiac ischemia-reperfusion in in vitro and in vivo models of myocardial 
reperfusion injury. We found enhanced L-2286-triggered Akt and GSK-3β phosphorylation 
not only in isolated hearts, but also in isoproterenol-induced cardiac injury. To our 
knowledge, this is the first ex vivo and in vivo report, which attributes a critical role to Akt in 
the cardioprotection afforded by PARP inhibitors. The PI3-kinase/Akt pathway is one of 
several prosurvival signaling routes, which is activated as an adaptive response to cellular 
stress.22,48 Among others, ischemia-reperfusion itself can expedite Akt signaling in cardiac 
myocytes, as shown in this study. However, L-2286 administration further increased Akt 
activation independently of cardiac injury, presumably exerting antiapoptotic and favorable 
metabolic effects. 
 Subsequently, this work demonstrated the differential activation of mitogen-activated 
protein kinases upon ischemia-reperfusion, which was clearly modulated by concomitant L-
2286 treatment, strongly depending on the context and timing of the deleterious insult. First, 
while ERK phosphorylation was enhanced upon ischemia-reperfusion of isolated hearts, 
 30 
isoproterenol in vivo caused a transient fall followed by a delayed increase in ERK activity. 
This is in accordance with reports showing that ERK activity reduced during ischemia ensued 
by its recovery during reperfusion in rat hearts.49-51 Based on ECG recordings, subcutaneous 
administration of isoproterenol provoked faster heart rate for at least 4 hours, implicating a 
prolonged “ischemic” period matching the duration of lower ERK activity (data not shown). 
Most importantly, L-2286 not only promoted ERK phosphorylation in normoxic and 
ischemic-reperfused isolated hearts, but also accelerated that in vivo covering the most 
vulnerable, first 4 hours immediately after isoproterenol administration. Although ERK is 
mainly involved in growth factor-induced signaling, it can play protective roles in oxidative 
stress via blocking apoptosis.22 Indeed, sustained activation of ERK during reoxygenation was 
shown to render delayed cytoprotection, probably by downregulating caspase-3 and JNK 
activity.52,53 In summary, the ability of L-2286 to elicit robust ERK activation in both ex vivo 
and in vivo ischemia-reperfusion may promote cardiac myocyte survival. 
 Second, phosphorylation of p38-MAPK exhibited a similar dynamics to that of ERK, 
i.e. a slight activation upon postischemic reperfusion in the Langendorff heart and a protracted 
activation 24 hours after isoproterenol administration. Our findings are thus consistent with 
reports where p38-MAPK was not activated by ischemia alone, but was stimulated by 
reperfusion in rat hearts.51,54 Remarkably, independently from the model used p38-MAPK 
phosphorylation was enhanced 2-3-fold in the presence of L-2286. The role of p38-MAPK in 
myocardial ischemia-reperfusion injury is controversial. Several data suggest that the 
activation of p38-MAPK/MAPKAPK2/Hsp-27 axis contributes to ischemic preconditioning, 
however, others concluded that p38-MAPK inactivation might be cardioprotective.23 This 
ambiguity might be reconciled knowing that two p38-MAPK isoforms (α and β) are 
expressed in the heart: while p38α transmits proapototic signals, p38β triggers hypertrophic 
response, i.e. promotes survival.55 Taken together, L-2286 expedited cardiac p38-MAPK 
phosphorylation, which might be protective under certain conditions. 
 Third, JNK was strongly activated by ex vivo ischemia-reperfusion and immediately 
after isoproterenol injection. In the in vivo model JNK thus responded differently from ERK 
and p38-MAPK demonstrating a sharp increase and a slow return (after 24 hours) in 
phosphorylation. Assuming a prolonged “ischemia” after isoproterenol administration lasting 
for several hours, our data are consistent with reported ischemia-induced activation of 
JNK.49,54 Although JNK was generally regarded as a proapoptotic kinase, recent studies 
suggested that JNK might only promote apoptosis in cells where the apoptotic program has 
already been initiated, also depending on the participation of other signaling molecules (such 
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as NF-κB).24 While L-2286 strengthened JNK phosphorylation in the Langendorff heart, it 
blocked that in isoproterenol-induced myocardial injury. The reasons behind these differences 
remain elusive; however, our in vivo model mimics more closely the pathophysiological 
events in myocardial infarction. Therefore, L-2286 may inhibit JNK activity during the most 
critical hours of the failing nutrient and oxygen supply. 
6.4 EFFECT OF PARP INHIBITION ON CELLULAR SIGNALING IN CHRONIC HEART FAILURE 
 Recent years have seen a burst in our understanding of the intracellular signaling 
mechanisms which mediate extrinsic and intrinsic growth stimuli into coordinated gene 
expression changes. Hypertrophy is initiated and maintained by vasoactive peptides, peptide 
growth factors, hormones and neurotransmitters, which all act upon MAP kinases, 
JAK/STAT, CaMK/calcineurin routes as well as glycogen synthase kinase-3ß.26,27,56-60 
Differential activation of MAPKs results in specific cardiac morphologic and functional 
phenotypes: while ERK1/2 activation leads to a concentric form of hypertrophy with 
enhanced cardiac function, p38-MAPK and JNK activation gives rise to maladaptive 
hypertrophy.26 Interestingly, JNK and p38-MAPK are activated in failing human hearts, while 
ERK activation remains at a physiologic level.26,28 Furthermore, several protein kinases 
including Akt, p70-S6 kinase, p90-RSK, protein kinase C and protein kinase A have been 
implicated in cardiac hypertrophy, commonly phosphorylating, thereby suppressing the 
antihypertrophic activity of GSK-3ß.25,28,57,61 The ability of GSK-3ß to inhibit hypertrophy in 
response to ß-adrenergic stimulation, pressure overload and calcineurin activation suggests 
that GSK-3ß represents a point of cross-talk and convergence of various hypertrophic 
signaling pathways.25,28,57,61 GSK-3ß phosphorylation via a phosphatidylinositol-3-kinase 
dependent pathway can be catalyzed by at least two protein kinases: Akt and insulin like 
kinase (ILK).56,61 Growth factors however can regulate GSK-3ß not only through the 
PI3K/Akt pathway, but also via an alternative PKC pathway.62 Most importantly, several 
PKC isoforms, i.e. PKCα, PKCβ, PKCγ, PKCη and PKCδ, can phosphorylate GSK-3ß at 
regulatory serine residues.63 Furthermore, altered gene expression of differential cardiac PKC 
isozymes including PKCδ, PKCα and PKCβI have been recently reported in myocardial 
hypertrophy.64-67 
 In this study eight weeks after myocardial infarction no increase in ERK1/2 and JNK 
activity was found in the heart samples, but a two-fold elevation in Akt and p38-MAPK 
phosphorylation was seen. Notably, upon L-2286 administration these kinase activities 
remained unaltered. By contrast, heart failure following ISO injections upregulated GSK-3ß 
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phosphorylation, which correlated with the activation of several PKC isoforms rather than that 
of Akt. Most importantly, PARP inhibition in the infarcted hearts simultaneously mitigated 
both GSK-3ß and PKC phosphorylation. Since GSK-3ß can integrate a variety of 
antihypertrophic signals and transmit them to NF-AT and c-Jun, the L-2286-induced PKC-
mediated GSK-3ß activation may have contributed to the rescue of failing hearts in our 
experimental model.43 
 The mechanism by which PARP inhibition diminished the activity of PKC still needs 
to be elucidated. Nevertheless, oxidative stress in chronic heart failure can increase PKC 
activation via various pathways. First, oxidative stress can directly or indirectly stimulate 
PKC via growth factor receptor phosphorylation or lipid secondary messengers (derived from 
the reactions of other receptor-regulated enzymes such as phospholipases A2, D and C).68 
Second, poly(ADP-ribose) polymerase activation could also contribute to PKC activation, 
because ROS-induced poly(ADP-ribosyl)ation depletes nicotinamide adenine dinucleotide 
(NAD+) pools or direct poly(ADP-ribosyl)ation blocks glycerinaldehyde 3-phosphate 
dehydrogenase (GAPDH) enzyme.69,70 The inhibition of GAPDH can divert the glycolytic 
flux towards the formation of α-glycerophosphate and diacylglycerol (DAG), the latter being 
the activator of PKC.70 On the other hand, reactive oxygen species can also directly oxidize 
and hinder GAPDH.71 
 Notably, PARP inhibition primarily interferes with the activity of nuclear PARP and, 
in turn, maintains NAD+ and ATP pools avoiding NAD+ depletion-induced inactivation of 
GAPDH. Furthermore, we have previously reported that PARP inhibitors could prevent the 
ROS-induced inactivation of mitochondrial respiratory complexes and the consequent 
mitochondrial ROS formation.3 We therefore suggest that PARP inhibition can blunt PKC 
activation eventually by preserving NAD+ pools and abrogating ROS production, thereby 
preempting GAPDH inactivation and DAG formation. 
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7. CONCLUSIONS 
 
 In conclusion, this study first demonstrates that PARP inhibition can beneficially 
influence the protein kinase signaling in isolated ischemic-reperfused hearts and 
isoproterenol-induced myocardial infarction by promoting Akt, ERK and p38-MAPK, but 
suppressing JNK activity. It is also the first report on changes in intracellular signaling during 
isoproterenol-induced myocardial infarction. Furthermore this work also provides evidence 
for the first time that PARP inhibition can halt the progression of cardiac hypertrophy into 
failure partially by promoting GSK-3ß activity via direct or indirect interruption of upstream 
protein kinase C signaling. Finally PARP inhibition is also reported to protect against cellular 
changes in the postinfarcted myocardium such as fibrosis, cardiomyocyte hypertrophy, 
mitochondrial dysfunction and fetal gene expression. The PARP inhibition-induced 
alterations in intracellular signaling upon myocardial ischemia-reperfusion and postinfarction 
ventricular remodeling further challenge the original dogma that protection by PARP 
inhibitors exclusively rely on the preservation of NAD+ as well as ATP stores. 
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